PEPTIDE-Fc FUSION THERAPEUTICS: APPLICATIONS AND CHALLENGES - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 137

95. Bugelski, P.J., Makropoulos, D. Spinka-Doms, T. Eirikis,
E. Volk, A. Jiao, Q. Huang, C. (2011) Differential Effects
of Long-lived Erythropoietin Receptor Agonists in Rats.
Pharmaceutica Analytica Acta 2:7.
96. Hutchins JT, Kull FC, Jr, Bynum J, Knick VC, Thurmond
LM, Ray P. (1995) Improved biodistribution, tumor targeting,
and reduced immunogenicity in mice with a gamma 4 variant
of Campath-1H. Proc. Natl. Acad. Sci. USA 92, 11980-
11984.
97. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W.
(2004) Structure-immunogenicity relationships of therapeutic
proteins. Pharm. Res. 21, 897-903.
98. Cromwell ME, Hilario E, Jacobson F. (2006) Protein aggre-
gation and bioprocessing. AAPS J. 8, E572-579.
99. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P,
Colombat P, et al. (2002) Therapeutic activity of humanized
anti-CD20 monoclonal antibody and polymorphism in IgG Fc
receptor FcgammaRIIIa gene. Blood 99, 754-758.
100. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al.
(2006) Engineered antibody Fc variants with enhanced
effector function. Proc. Natl. Acad. Sci. USA 103, 4005-
4010.
101. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG,
et al. (2002) Lack of fucose on human IgG1 N-linked oligo-
saccharide improves binding to human Fcgamma RIII and
antibody-dependent cellular toxicity. J. Biol. Chem. 277,
26733-26740.
102. Crispin M, Bowden TA, Coles CH, Harlos K, Aricescu AR,
Harvey DJ, et al. (2009) Carbohydrate and domain architec-
ture of an immature antibody glycoform exhibiting enhanced
effector functions. J. Mol. Biol. 387, 1061-1066.
103. Raju TS. (2008) Terminal sugars of Fc glycans influence
antibody effector functions of IgGs. Curr. Opin. Immunol. 20,
471-478.

104. Xu D, Alegre ML, Varga SS, Rothermel AL, Collins AM,
Pulito VL, et al. (2000) In vitro characterization of five
humanized OKT3 effector function variant antibodies. Cell
Immunol. 200, 16-26.
105. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W,
Gottlieb P, et al. (2009) Treatment of patients with new onset
type 1 diabetes with a single course of anti-CD3 mAb
Teplizumab preserves insulin production for up to 5 years.
Clin. Immunol. 132, 166-173.
106. Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS,
Holst JJ. (2011) An overview of once-weekly GLP-1 recep-
tor agonists—available efficacy and safety data and
perspectives for the future. Diabetes Obes. Metab. 60,
1599-1607.
107. Chu QS. (2009) Aflibercept (AVE0005): an alternative
strategy for inhibiting tumour angiogenesis by vascular
endothelial growth factors. Expert Opin. Biol. Ther. 9,
263-271.
108. Mack GS. (2008) CD20 blockers eye crowded rheumatology
market. Nat. Biotechnol. 26, 1053-1054.
109. Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA,
Grosmaire LS, Tan P, et al. (2009) CD20-directed
small modular immunopharmaceutical, TRU-015, depletes
normal and malignant B cells. Clin. Cancer Res. 15,
2739-2746.
110. Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu
C, Bannink J. (2008) Pharmacokinetic and pharmacodynamic
properties of TRU-015, a CD20-directed small modular
immunopharmaceutical protein therapeutic, in patients with
rheumatoid arthritis: a Phase I, open-label, dose-escalation
clinical study. Clin. Ther. 30, 1806-1816.
111. Saerens D, Ghassabeh GH, Muyldermans S. (2008) Single-
domain antibodies as building blocks for novel therapeutics.
Curr. Opin. Pharmacol. 8, 600-608.